What is the glow stack?

A combination sold online, usually GHK-Cu with BPC-157 and TB-500, presented as an injectable route to better skin, hair and general 'glow'. Two of the three are research compounds that are not approved drugs and not cosmetic ingredients; the third, GHK-Cu, is a legitimate cosmetic ingredient that is also sold in vial form for research use. The stack is a marketing construct, not a studied protocol: no published trial has tested these three together for anything.

Does the glow stack have any clinical evidence?

For appearance, none that we could find. Counted on 2026-09-06, BPC-157 has zero randomized controlled trials indexed on PubMed for any indication and two small clinic pilots in humans. Thymosin beta-4 has three randomized trials, two of them in venous leg ulcers, measuring wound closure rather than skin quality. Copper peptides have one indexed randomized trial on skin, which found no objective benefit. Nothing in that record was designed to answer whether anyone looks better.

The honest answer is that nobody knows at the level a safety question deserves. The published human safety data amount to a two-person intravenous infusion pilot and a twelve-woman pilot in interstitial cystitis, both from one private clinic. The FDA has identified potential immunogenicity risk for certain routes of administration and complexity in characterizing the active ingredient and its impurities. It is not an approved drug in the United States, and material sold online is not made to any enforced standard.

Is TB-500 the same as thymosin beta-4?

Not exactly, and the difference matters when reading studies. Thymosin beta-4 is a 43-amino-acid peptide; TB-500 as sold is generally a fragment of it, and the FDA's safety-risk entry names the fragment LKKTETQ specifically. The venous-ulcer trials used thymosin beta-4 itself, applied topically. Citing those trials as evidence for an injected fragment sold online is citing a different molecule by a different route for a different purpose.

Do people use the glow stack for skin?

Sellers market it that way and forum posts describe it, which is why the term has search volume. What does not exist is a trial. The regulatory record points the other way: at the FDA's July 2026 compounding advisory meeting, BPC-157 was being evaluated for ulcerative colitis and TB-500 for wound healing. Appearance is not a use anyone has taken to a regulator.

Is GHK-Cu in the glow stack the same as a copper peptide serum?

Same molecule, different product category and different evidence. As a cosmetic ingredient in a serum, GHK-Cu is regulated as a cosmetic and has the small trial record we describe on our copper peptides page. Sold in a vial as a research compound for reconstitution and injection, it is outside cosmetics regulation entirely and has no human trial for appearance by that route. The word on the label is the same; almost nothing else is.

Is the glow stack legal?

The compounds are generally sold as research chemicals, labelled not for human consumption, which is a statement about the seller's intended use rather than a safety finding. BPC-157 and TB-500 are not approved drugs in the US and are not approved cosmetic ingredients. Both also appear in anti-doping analytical literature, so competitive athletes have a separate problem. Legal questions about a specific purchase belong with a lawyer, and medical ones with a clinician; this page reports what the record contains.

The Glow Stack: GHK-Cu, BPC-157 and TB-500, Counted

Zero randomized trials for BPC-157, three for thymosin beta-4, one for copper peptides, plus what the FDA says about compounding both.

"Glow stack" is one of the fastest-growing search terms in beauty peptides, and it names something the beauty industry did not make: a combination of GHK-Cu with two injectable research compounds, BPC-157 and TB-500, sold online with before-and-after photographs. This page does what the sellers' pages do not, which is count the evidence. We ran the census on PubMed on 2026-09-06 and read the FDA's own documents on both compounds. The short version is that the stack's two distinctive ingredients have been evaluated by regulators for ulcerative colitis and for leg ulcers, and by nobody for appearance.

The census

PubMed, searched 2026-09-06, title and abstract terms, counts reproducible by anyone.

Compound	All records	Indexed as human	Randomized controlled trials	Trials on skin appearance
BPC-157	221	49	0	0
Thymosin beta-4 / TB-500	622	343	3	0
GHK-Cu / copper tripeptide	—	47	1	1 (negative on objective endpoints)

The 49 "human" BPC-157 records are mostly reviews, orthopaedic commentary and doping-control analytical chemistry — papers about detecting the compound in athletes' blood rather than about giving it to anyone. Two are actual human studies, and both are pilots from one private clinic:

An intravenous safety pilot in two people. A 58-year-old man and a 68-year-old woman, both of whom had received intravenous BPC-157 before, were infused with 10 mg on day one and 20 mg on day two, with blood work and vitals around each infusion. No measurable effects on cardiac, liver, kidney, thyroid or glucose markers and no reported side effects. The authors' own conclusion asks for future studies to confirm safety (Lee and Burgess, Altern Ther Health Med 2025).
A twelve-woman interstitial-cystitis pilot using BPC-157 made by a 503A compounding pharmacy, in a condition with no effective treatment (Lee et al., Altern Ther Health Med 2024).

Neither concerns skin. Two participants is not a safety database, and the paper says so.

What thymosin beta-4's trials measured

Thymosin beta-4 has the most substantial evidence of the three, and it is wound-healing evidence. The largest trial we could open randomized 73 patients with venous stasis ulcers across eight European sites, five in Italy and three in Poland, in a double-blind, placebo-controlled, dose-escalation Phase 2 study of topical thymosin beta-4. Safety at all doses was comparable to placebo; the 0.03% dose was reported as potentially accelerating healing, with complete wound healing within three months in about 25% of patients, particularly those with smaller or milder ulcers (Guarnera et al., Ann N Y Acad Sci 2010; an earlier report of the same European programme appeared in 2007).

That is a real result in a serious condition. It was topical, on open ulcers, with the full-length 43-amino-acid peptide. TB-500 as sold online is generally a fragment — the FDA's safety entry names LKKTETQ — injected, for appearance. Every term in that sentence differs from the trial.

What the FDA has actually said

Both compounds appear on the FDA's list of bulk drug substances that may present significant safety risks, in the section for substances nominated for compounding use and then withdrawn (page last updated 22 April 2026):

BPC-157 — compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization."
Thymosin Beta-4, Fragment (LKKTETQ) — compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities."

Immunogenicity means the body may mount an immune response to the injected peptide. "Complexities with regard to API characterization" means it is hard to establish what is actually in the vial. Both compounds returned to the FDA's Pharmacy Compounding Advisory Committee on 23-24 July 2026, where BPC-157 (free base and acetate) was evaluated for ulcerative colitis and TB-500 for wound healing. Advisory committee recommendations are non-binding, and neither compound is an approved drug.

Nowhere in that record does appearance appear. The regulatory conversation about these two compounds is a conversation about the gut and about open wounds.

The copper part, which is different

GHK-Cu is the one member of the stack that is a legitimate cosmetic ingredient, sold in serums, assessed by the Cosmetic Ingredient Review and used at measurable concentrations. Its skin trial record is small and mixed: the single randomized trial indexed on PubMed put 13 CO2-laser-resurfacing patients on regimens with or without GHK-Cu and found no significant difference in erythema, wrinkles or skin quality by blinded objective assessment, with only patient-reported satisfaction differing (Miller et al., Arch Facial Plast Surg 2006). A sponsor-funded 40-woman trial reported a larger wrinkle-volume reduction than vehicle. Our copper peptides page has all of it.

The distinction the stack blurs: a copper peptide in a serum and a copper peptide in a vial for reconstitution are the same molecule under different rules, with different evidence, and only one of them has any human appearance data at all.

What a reader of the marketing should notice

Three things, none of which requires a chemistry degree.

No trial has ever tested this combination. Not for glow, not for skin, not for anything. Combination claims in this category are assembled from single-compound papers about other conditions.

The before-and-after photographs are not evidence. No trial in this literature published photographs as an endpoint; the wound trials measured closure and the cosmetic trials measured instrument readings. A photograph from a seller has no lighting protocol, no control and no blinding.

"Research compound" is a statement about the seller. A vial labelled not for human consumption is a description of the intended use the seller asserts, not a finding about safety or purity. The FDA's own note about difficulty characterizing the active ingredient and its impurities applies with more force to material made outside any enforced standard. The reporting on vendor conduct in this market is PeptiFact's territory, and the strength-of-evidence audit for the same compounds in a performance context is on MuscleLedger's Wolverine-stack page.

What would change this page

A randomized controlled trial of any of these three compounds with an appearance endpoint, or a published safety database larger than fourteen people. Neither exists today. If one appears, this page will be updated with it, and the census above can be re-run by anyone against the same search terms.

Meanwhile, the ingredients with actual cosmetic evidence are covered in peptides for skin and ranked in best peptides for skin. Our testing notes explain the standard this publication holds itself to.

Sources

PubMed census run 2026-09-06 via NCBI E-utilities esearch; terms: "BPC 157"[tiab] OR "BPC-157"[tiab] and "thymosin beta-4"[tiab] OR "thymosin beta 4"[tiab] OR "TB-500"[tiab], with humans[mh] and randomized controlled trial[pt] filters. PubMed.
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025;31(5):20-24. PubMed 40131143.
Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024;30(10):12-17. PubMed 39325560.
Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci 2010;1194:207-12. PubMed 20536470.
Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci 2007;1112:407-12. PubMed 17495250.
Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006;8(4):252-9. PubMed 16847171.
US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page last updated 22 April 2026, accessed 2026-09-06. FDA.
US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Accessed 2026-09-06. FDA.

Published by Peptide Glow Journal Editorial. Nothing on this page is a recommendation to use any compound, and no product is ranked, scored or affiliate-linked.